维拉克塔计划探索战略选择

2024-12-27 22:04

Cancer drug developer Viracta Therapeutics (NASDAQ:VIRX) traded ~15% lower in the premarket on Friday after announcing plans to explore strategic alternatives, including a sale or a merger deal, to maximize shareholder value.
Concurrently, the company announced it would close its pivotal Phase 2 clinical trial for its lead candidate, Nana-val, in relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma.
The Cardiff, California-based biotech stressed that its decision to close the NAVAL-1 trial reflected its aim to extend cash runway and was unrelated to any new safety finding. Meanwhile, its discussions on strategic alternatives have already started.
“I continue to believe that Nana-val has the potential to improve the treatment of relapsed/refractory EBV+ lymphomas, and I remain hopeful that it will one day be approved,” CEO Mark Rothera added.

More on Viracta Therapeutics